SugarCone Biotech LLC will be represented at ASCO by Paul D Rennert, Founder & Principal of the Company. SugarCone is actively sourcing innovative therapeutic programs that address unmet needs in cancer treatment. Our goal at ASCO is to continue to build upon our deep expertise in understanding the drug development landscape across tumor classes. While we focus intently on biologics and immune checkpoint therapeutics, we also have intensive experience with small molecule drug development programs. This unique breadth of clinical expertise, deep tumor biology experience and comprehensive understanding of different therapeutic classes has placed us in the center of the recent surge in successful cancer drug development. Specifically, SugarCone brings programs to partners who are committed to the clinical development of important new therapeutics. We also specialize in working closely with preclinical companies to nurture and mature their drug development programs in order to effectively address the evolving clinical landscape.
We have been very pleased to see our clients successfully develop partnerships with top tier biopharma, including Celgene, Bristol-Myers Squibb and Immunogen. Such success provides well-deserved validation, and the capital to build for the future.
Contact us at firstname.lastname@example.org or cell/text us at 1-508-282-6370.
See you in Chicago!